

MASTER INTELLIGENCE DOSSIER: UK COVID-19 PUBLIC MONEY FLOW & PROCUREMENT (2020–2022)

Lead Investigator: Andrew Sibley | Initiative: JAOC Investigations (www.jaoc.org.uk)

1. Operational Overview & Core Architecture

Between 2020 and 2022, HM Treasury committed over **£400 billion** in emergency pandemic funding. While justified under emergency health and economic stabilization mandates, subsequent investigations into the operational pipelines reveal systematic vulnerabilities: expedited non-competitive tendering, VIP procurement lanes, complex multi-tier intermediaries, and opaque corporate ownership networks that transferred massive public wealth into private equity and shareholder profits.

Associated Visual Evidence Artifacts (Google Drive Registry):

- **Artifact A:** UK COVID-19 Procurement - Top Suppliers, Money Flow & Key Actors (2020-2022) [\[View File\]](#)
- **Artifact B:** UK COVID-19 Public Money Flow 2020-2022 [\[View File\]](#)

2. Macro Money Flow Breakdown: Treasury to End Recipients

Tier 1: Source of Funds (Where the Money Originated)

- **HM Treasury (£400bn+):** Total COVID-19 support (2020–2022) sourced via general taxation, government borrowing, and Bank of England facilities.
- **Department of Health & Social Care (DHSC):** £37.8bn allocated for testing, PPE, vaccines, and direct NHS responses.
- **Cabinet Office:** £16.7bn for COVID procurement, PPE, test & trace, and high-priority logistics (HPL).
- **Department for Business & Trade / BEIS:** £80.4bn deployed via loan schemes (Bounce Back Loans, CBILS, CLBILS).
- **Home Office:** £5.6bn covering border controls, quarantine facilities, and security contracts.
- **Ministry of Defence:** £6.8bn for logistics, PPE, and operational support.
- **Devolved Administrations & International Funds:** £3bn+ across Scotland, Wales, and Northern Ireland, alongside £18bn in EU/international research and vaccine development funds.

Tier 2: Allocation & Intermediary Delivery Channels

- **Cabinet Office & BEIS:** Managed overarching coordination, ministerial committees (COBR), and business support frameworks.

- **British Business Bank (BBB):** Administered ~£80.4bn across CBILS, CLBILS, BBLS, and the Future Fund (£1.1bn).
- **NHS England & Integrated Care Boards / UKHSA / Crown Commercial Service (CCS):** Acted as direct operational channels for procurement frameworks, test and trace programs, and clinical supply chains.

3. Top Suppliers & Contract Concentration (2020–2022)

A significant proportion of emergency procurement was concentrated among a select group of high-value private contractors:

Rank	Supplier / Entity	Approx. Contract Value	Primary Goods / Services	Parent / Major Shareholder
1	Innova Medical Group	£4.2bn	Lateral flow testing	Pasaca Capital (US)
2	Full Support Healthcare	£1.85bn	PPE (gowns, gloves, masks)	FSI + Full Support Industries Ltd
3	Tanner Pharma UK	£1.45bn	PPE (surgical gowns, masks)	75%+ Raymond F. Bourne
4	G4S Facilities Mgmt (UK)	£1.4bn	Security, testing, facilities	Allied Universal ownership
5	Global Access Diagnostics	£1.15bn	Test manufacturing	Founders linked to Mologic; Gates Foundation / FIND backing
6	Iovia	£1.1bn	Test kits, logistics	Ownership structure under review
7	Medco Solutions	£900m	PPE, medical supplies	UK private company (ownership TBC)
8	Royal Mail Group	£850m	Vaccine & test logistics	Listed (LSE: RMG)
9	Uniserve	£850m	PPE logistics, freight	75%+ Uniserve Holdings Ltd
10	Serco	£800m	Testing, vaccination, vulnerable support	Serco Group plc (LSE: SRP)

Additional notable high-value contractors include PPE Medpro (£776m, subject to inquiry), Randox Laboratories (£777m), Sitel Group (£572m), Deloitte (£545m), Capita (£533m), Palantir UK (£330m), AstraZeneca (£423m+), Pfizer (£279m+), and Moderna (£146m+).

4. Key Actors, Political Connections & Corporate Governance

- **Political & Ministerial Oversight:** Key government ministers (Chancellor, Secretaries of State for Business & Health), Permanent Secretaries, and Accounting Officers oversaw allocation frameworks.
- **VIP Lane & Patronage:** Documented connections between political figures and specific suppliers (e.g., Baroness Mone's links to PPE Medpro; Dr Charles Huang / Pasaca Capital with Innova; Dr Peter FitzGerald with Randox).
- **Advisors & Oversight Bodies:** Engagement of consulting firms (McKinsey, Deloitte, PwC, KPMG, Boston Consulting Group) alongside scientific advisory bodies (SAGE, NERVTAG) and statutory watchdogs (National Audit Office).

5. End Outcomes & Wealth Accumulation

- **Exponential Revenue Growth:** Surging corporate turnovers across diagnostic, PPE, and logistics contractors.
- **Private Equity & Shareholder Returns:** Multi-year government contracts translating into substantial shareholder dividends, executive remuneration spikes, and international expansion.
- **Asset Accumulation:** Long-term commercial revenue establishing permanent market footholds for firms initially engaged under emergency dispensations.

6. Investigative Roadmap & Next Steps

1. **FOI & Contract Extraction:** Securing full, unredacted contracts, variations, and correspondence logs via Freedom of Information (FOI) and EIR requests.
2. **Corporate Mapping:** Tracing ultimate beneficial owners, offshore holding entities, and corporate registry filings across UK and international jurisdictions.
3. **Decision-Maker Accountability:** Identifying specific political and civil service decision-makers responsible for non-competitive contract sign-offs.
4. **Financial Forensics:** Correlating contract values with company profit disclosures, dividend distributions, and asset acquisitions.
5. **Regulatory Escalation:** Preparing formal submissions for the Scottish Public Services Ombudsman, Information Commissioner's Office, and relevant audit authorities.

© 2026 JAOC Investigations (www.jaoc.org.uk). All rights reserved.

Lead Investigator: Andrew Sibley. This intelligence dossier is published under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), permitting non-commercial reproduction with explicit attribution to JAOC Investigations.